Form 4: Quince Therapeutics CEO Transfers Shares to Trust

Quince Therapeutics CEO and CMO Dirk Thye transferred 739,885 common shares from direct ownership to an indirect ownership via the Thye Trust.

Summary

• Dirk Thye, CEO and CMO of Quince Therapeutics, Inc. (QNCX), reported a change in beneficial ownership of common shares.
• On December 10, 2025, Thye disposed of 739,885 common shares from his direct ownership.
• Concurrently, 739,885 common shares were acquired indirectly by the Thye Trust.
• Both transactions were reported with a price of $0, indicating a gift or transfer.
• Following these transactions, Thye directly owns 255,000 common shares and indirectly owns 739,885 common shares through the Thye Trust.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The filing is neutral as it reports an internal transfer of shares by an insider for estate planning purposes, which typically has no direct positive or negative impact on the company's operational or financial outlook.

Positives

• The transaction represents a planned change in ownership structure, likely for estate planning, and does not indicate a sale of shares into the open market.

Negatives

• The transaction does not directly impact the company's operational or financial performance.

Future Outlook

This filing is a report of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

This insider transaction is a personal financial planning event for a key executive and does not reflect broader industry trends or competitive dynamics.

Related Party Transactions

• Dirk Thye transferred 739,885 common shares from his direct ownership to the Thye Trust, which is considered a related party transaction due to his beneficial interest in the trust.

Stakeholder Impact

• Shareholders: Minimal direct impact as the total beneficial ownership of the insider remains unchanged, only the form of ownership has shifted.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders as the transaction is a personal financial matter for an executive.

Key Dates

Keywords

Quince Therapeutics, QNCX, Dirk Thye, Form 4, Insider Transaction, Share Transfer, Trust, CEO, CMO, Beneficial Ownership